Faruqi and Faruqui, LLP Logo
Share this page

SCYNEXIS, Inc. (SCYX)

NASDAQ:SCYX

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In SCYNEXIS, Inc. To Contact The Firm Before Lead Plaintiff Deadline

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (NASDAQ:SCYX) of the May 8, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all those who purchased SCYNEXIS securities in connection with the Company’s initial public offering on or about May 2, 2014 (the “IPO”); and/or between May 2, 2014 and March 2, 2017 (the “Class Period”).  The case, GIBSON v. SCYNEXIS, INC. et al, 2:17-cv-01565 was filed on March 8, 2017, and has been assigned to Judge Katharine Sweeney Hayden.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) SCYNEXIS’ lead product candidate, SCY-078, entailed substantial undisclosed health and safety risks; (ii) consequently, the Company had overstated the drug’s approval prospectus and/or commercial viability; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Specifically, after market close on March 2, 2017, SCYNEXIS announced that the Food and Drug Administration (“FDA”) had placed a clinical hold on clinical trials for the intravenous formulation of the Company's lead product candidate SCY-078.

On this news, SCYNEXIS’ share price fell from $3.27 per share on March 2, 2017 to a closing price of $2.70on March 3, 2017—a $0.57 or a 17.43% drop.

Take Action

If you invested in SCYNEXIS securities pursuant to the IPO and/or during the Class Period and would like to discuss your legal rights, please fill out the form below. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding SCYNEXIS’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    SCYNEXIS, Inc. (SCYX)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 03/15/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.